Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Post-COVID Condition, Fatigue Symptom

In brief

The primary purpose of this phase 2a study is to compare the efficacy of abrocitinib to placebo in improving severe fatigue in non-hospitalized adults with symptomatic Post-COVID Condition (PCC) (also called Long COVID). We are also interested in learning if abrocitinib is effective in improving overall health status in people suffering from severe fatigue from PCC. Eligible participants with a confirmed history of COVID19 infection who also have PCC according to the World Health Organization definition, will be randomized to receive abrocitinib at a dose of 50 mg, 100 mg, or placebo by mouth daily for 12 weeks (84 days).

Key facts

Study ID

NCT06597396

Run by

Beth Israel Deaconess Medical Center

People needed

46

Starts

2024-12-27

Expected to finish

2026-09-30

Last updated by the study team

2026-04-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• History of confirmed COVID-19 infection
• PCC diagnosis according to the WHO definition as occurring in individuals with a history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 that lasts for at least 2 months and cannot be explained by an alternative diagnosis
• Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures
• Capable of giving signed informed consent

You may not qualify if…

• Participants with acute and chronic infections, history of specific recurrent infections
• Suspected or confirmed active SARS-CoV-2 infection within past 30 days
• Some cardiac conditions
• Any current tobacco smoker or person who has smoked tobacco products within 12 months of screening, or former tobacco smoker ≥ 50 years old
• Known to be infected with Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C, Herpes Virus, or Tuberculosis
• History of immunodeficiency
• Blood clotting conditions
• Must meet general screening laboratory criteria
• Allergy or other contraindication to any of the components of the study intervention
• Known prior participation in this trial or other trial involving abrocitinib
• Concurrent therapy with a JAK or TYK2 inhibitor
• Other protocol criteria apply

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.